PURPOSE: The purpose of this work was to evaluate the patient-borne financial cost of common, adverse breast cancer treatment-associated effects, comparing cost across women with or without these side effects. METHODS: Two hundred eighty-seven Australian women diagnosed with early-stage breast cancer were prospectively followed starting at 6 months post-surgery for 12 months, with three monthly assessments of detailed treatment-related side effects and their direct and indirect patient costs attributable to breast cancer. Bootstrapping statistics were used to analyze cost data, and adjusted logistic regression was used to evaluate the association between costs and adverse events from breast cancer. Costs were inflated and converted from 2002 Australian to 2014 US dollars. RESULTS: More than 90 % of women experienced at least one adverse effect (i.e., post-surgical issue, reaction to radiotherapy, upper-body symptoms or reduced function, lymphedema, fatigue, or weight gain). On average, women paid $5,636 (95 % confidence interval (CI), $4,694, $6,577) in total costs. Women with any one of the following symptoms (fatigue, reduced upper-body function, upper-body symptoms) or women who report ≥4 adverse treatment-related effects, have 1.5 to nearly 4 times the odds of having higher healthcare costs than women who do not report these complaints (p < 0.05). CONCLUSIONS: Women face substantial economic burden due to a range of treatment-related health problems, which may persist beyond the treatment period. Improving breast cancer care by incorporating prospective surveillance of treatment-related side effects and strategies for prevention and treatment of concerns (e.g., exercise) has real potential for reducing patient-borne costs.
PURPOSE: The purpose of this work was to evaluate the patient-borne financial cost of common, adverse breast cancer treatment-associated effects, comparing cost across women with or without these side effects. METHODS: Two hundred eighty-seven Australian women diagnosed with early-stage breast cancer were prospectively followed starting at 6 months post-surgery for 12 months, with three monthly assessments of detailed treatment-related side effects and their direct and indirect patient costs attributable to breast cancer. Bootstrapping statistics were used to analyze cost data, and adjusted logistic regression was used to evaluate the association between costs and adverse events from breast cancer. Costs were inflated and converted from 2002 Australian to 2014 US dollars. RESULTS: More than 90 % of women experienced at least one adverse effect (i.e., post-surgical issue, reaction to radiotherapy, upper-body symptoms or reduced function, lymphedema, fatigue, or weight gain). On average, women paid $5,636 (95 % confidence interval (CI), $4,694, $6,577) in total costs. Women with any one of the following symptoms (fatigue, reduced upper-body function, upper-body symptoms) or women who report ≥4 adverse treatment-related effects, have 1.5 to nearly 4 times the odds of having higher healthcare costs than women who do not report these complaints (p < 0.05). CONCLUSIONS:Women face substantial economic burden due to a range of treatment-related health problems, which may persist beyond the treatment period. Improving breast cancer care by incorporating prospective surveillance of treatment-related side effects and strategies for prevention and treatment of concerns (e.g., exercise) has real potential for reducing patient-borne costs.
Authors: Louisa G Gordon; Paul Scuffham; Diana Battistutta; Nick Graves; Margaret Tweeddale; Beth Newman Journal: Breast Cancer Res Treat Date: 2005-11 Impact factor: 4.872
Authors: Cheryl L Rock; Colleen Doyle; Wendy Demark-Wahnefried; Jeffrey Meyerhardt; Kerry S Courneya; Anna L Schwartz; Elisa V Bandera; Kathryn K Hamilton; Barbara Grant; Marji McCullough; Tim Byers; Ted Gansler Journal: CA Cancer J Clin Date: 2012-04-26 Impact factor: 508.702
Authors: Maria Pisu; Andres Azuero; Karen Meneses; Jeffrey Burkhardt; Patrick McNees Journal: Breast Cancer Res Treat Date: 2010-10-26 Impact factor: 4.872
Authors: Michael J Hassett; A James O'Malley; Juliana R Pakes; Joseph P Newhouse; Craig C Earle Journal: J Natl Cancer Inst Date: 2006-08-16 Impact factor: 13.506
Authors: Ann Marie Flores; Jason Nelson; Lee Sowles; Rebecca G Stephenson; Kathryn Robinson; Andrea Cheville; Antoinette P Sander; William J Blot Journal: Phys Ther Date: 2020-03-10
Authors: Tessa De Vrieze; Nick Gebruers; Ines Nevelsteen; Wiebren A A Tjalma; Sarah Thomis; An De Groef; Lore Dams; Vincent Haenen; Nele Devoogdt Journal: Support Care Cancer Date: 2020-11-24 Impact factor: 3.603
Authors: Jennifer Baima; Sara-Grace Reynolds; Kathryn Edmiston; Anne Larkin; B Marie Ward; Ashling O'Connor Journal: J Cancer Educ Date: 2017-06 Impact factor: 2.037
Authors: Betty Smoot; Steven M Paul; Bradley E Aouizerat; Laura Dunn; Charles Elboim; Brian Schmidt; Deborah Hamolsky; Jon D Levine; Gary Abrams; Judy Mastick; Kimberly Topp; Christine Miaskowski Journal: Am J Phys Med Rehabil Date: 2016-09 Impact factor: 2.159
Authors: Sveinung Berntsen; Neil K Aaronson; Laurien Buffart; Sussanne Börjeson; Ingrid Demmelmaier; Maria Hellbom; Pernille Hojman; Helena Igelström; Birgitta Johansson; Ronnie Pingel; Truls Raastad; Galina Velikova; Pernilla Åsenlöf; Karin Nordin Journal: BMC Cancer Date: 2017-03-27 Impact factor: 4.430
Authors: Lorraine T Dean; Kathryn H Schmitz; Kevin D Frick; Lauren H Nicholas; Yuehan Zhang; S V Subramanian; Kala Visvanathan Journal: J Cancer Surviv Date: 2018-01-25 Impact factor: 4.442